Objectives: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection. Design: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires. Results: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls. Conclusion: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls. Trial registration number: NCT04691895.

Post COVID-19 irritable bowel syndrome / G. Marasco, C. Cremon, M.R. Barbaro, G. Cacciari, F. Falangone, A. Kagramanova, D. Bordin, V. Drug, E. Miftode, P. Fusaroli, S.Y. Mohamed, C. Ricci, M. Bellini, M.M. Rahman, L. Melcarne, J. Santos, B. Lobo, S. Bor, S. Yapali, D. Akyol, F.P. Sapmaz, Y.Y. Urun, T. Eskazan, A. Celebi, H. Kacmaz, B. Ebik, H.C. Binicier, M.S. Bugdayci, M.B. Yağcı, H. Pullukcu, B.Y. Kaya, A. Tureyen, İ. Hatemi, E.S. Koc, G. Sirin, A.R. Calıskan, G. Bengi, E.E. Alıs, S. Lukic, M. Trajkovska, K. Hod, D. Dumitrascu, A. Pietrangelo, E. Corradini, M. Simren, J. Sjölund, N. Tornkvist, U.C. Ghoshal, O. Kolokolnikova, A. Colecchia, J. Serra, G. Maconi, R. De Giorgio, S. Danese, P. Portincasa, A. Di Sabatino, M. Maggio, E. Philippou, Y.Y. Lee, D. Salvi, A. Venturi, C. Borghi, M. Zoli, P. Gionchetti, P. Viale, V. Stanghellini, G. Barbara. - In: GUT. - ISSN 0017-5749. - 72:3(2023 Mar), pp. 484-492. [10.1136/gutjnl-2022-328483]

Post COVID-19 irritable bowel syndrome

G. Maconi
Writing – Review & Editing
;
2023

Abstract

Objectives: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection. Design: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires. Results: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls. Conclusion: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls. Trial registration number: NCT04691895.
COVID-19; irritable bowel syndrome
Settore MED/12 - Gastroenterologia
mar-2023
9-dic-2022
GUT
Article (author)
File in questo prodotto:
File Dimensione Formato  
Marasco et al. Gut 2023.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1005608
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 27
social impact